Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviva, Inc.INVA · Entity 4679 | Sr. VP & Chief Scientific Off. | August 20, 2018 | August 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviva, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 247,767 |
Ending reported balance
After 2018-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-20 · Tax withholding · Disposed 3,089 · Balance 256,271 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Row 2 · 2018-08-21 · Sale · Disposed 8,504 · Balance 247,767 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.1000 to $14.1450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.1000 to $14.1450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2018 Filed Aug 22, 2018 22:43 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 8,504 | $14.12 | $120,079.88 |
DisclosureSEC source: 0001567619-18-001671 · doc1.xml · nonDerivative · entry 2 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,767 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.1000 to $14.1450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 22:43 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 3,089 | $14.08 | $43,493.12 |
DisclosureSEC source: 0001567619-18-001671 · doc1.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,271 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:47 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 3,089 | $14.59 | $45,068.51 |
DisclosureSEC source: 0001179110-18-007379 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,360 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. F2 · balance_after: Includes 432 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2018. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:13 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 74,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003601 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,017 F1 · shares: Includes 24,814 shares of common stock granted pursuant to a time-based restricted stock unit award (RSU). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2019, and 6.25% on May 20, 2019, 6.25% on August 20, 2019, 6.25% on November 20, 2019, 6.25% on February 20, 2020, 6.25% on May 20, 2020, 6.25% on August 20, 2020 and remaining 37.5% on November 20, 2020, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes shares of common stock granted pursuant to a performance-based restricted stock unit award (PSU). The shares vest pursuant to the PSU over a 31-month performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 24,815, but the actual number of shares that may vest will range from 0 to 49,630 shares based on the Issuer's relative TSR over the performance period. Subject to achievement of the performance-based vesting conditions, the shares eligible to vest based on achievement will vest on November 20, 2021 provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 21:23 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 9,890 | $16.60 | $164,148.29 |
DisclosureSEC source: 0001179110-18-002590 · edgar.xml · nonDerivative · entry 2 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,573 F2 · shares: This sale was effected for tax planning purposes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.58 to $16.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Includes 363 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2017. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:23 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 16,700 | $16.44 | $274,548.00 |
DisclosureSEC source: 0001179110-18-002590 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,463 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| November 21, 2017 Filed Nov 22, 2017 21:53 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 13,000 | $13.29 | $172,794.70 |
DisclosureSEC source: 0001179110-17-014575 · edgar.xml · nonDerivative · entry 2 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,800 F2 · shares: This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:53 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 14,757 | $13.17 | $194,349.69 |
DisclosureSEC source: 0001179110-17-014575 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,800 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 20:34 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 2,596 | $12.28 | $31,878.88 |
DisclosureSEC source: 0001179110-17-011726 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,557 F1 · shares: The shares were withheld by the Company to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| May 22, 2017 Filed May 23, 2017 20:16 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 7,815 | $12.01 | $93,858.15 |
DisclosureSEC source: 0001179110-17-007836 · edgar.xml · nonDerivative · entry 2 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,153 F2 · shares: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: This sale was effected for tax planning purposes. F4 · balance_after: Includes 776 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2017. Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:16 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 2,590 | $11.86 | $30,717.40 |
DisclosureSEC source: 0001179110-17-007836 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,968 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 21:28 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 6,367 | $12.04 | $76,658.68 |
DisclosureSEC source: 0001179110-17-002896 · edgar.xml · nonDerivative · entry 1 Witek Theodore J. Jr. · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,782 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:22 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 106,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001080 · edgar.xml · nonDerivative · entry 1 WITEK THEODORE L JR · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,149 F1 · shares: Includes 53,358 shares of common stock granted pursuant to a time-based restricted stock unit award (RSU). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2018, and 6.25% on May 20, 2018, 6.25% on August 20, 2018, 6.25% on November 20, 2018, 6.25% on February 20, 2019, 6.25% on May 20, 2019, 6.25% on August 20, 2019 and the remaining 37.5% on November 20, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes shares of common stock granted pursuant to a performance-based restricted stock unit award (PSU). The shares vest pursuant to the PSU over a two-year and 32-month performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 26,680, but the actual number of shares that may vest will range from 0 to 53,360 shares based on the Issuer's relative TSR over the performance periods. Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2019 and the remaining one-third of such shares will vest on November 20, 2019 and (ii) the share eligible to vest based on achievement for the 32-month performance period will vest on November 20, 2019, in each case, (continued in Footnote 3) F3 · shares: (continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:40 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 3,700 | $10.84 | $40,122.80 |
DisclosureSEC source: 0001179110-16-031971 · edgar.xml · nonDerivative · entry 2 WITEK THEODORE L JR · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,431 F2 · balance_after: Includes 701 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2016. Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 22:40 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 1,487 | $10.91 | $16,223.17 |
DisclosureSEC source: 0001179110-16-031971 · edgar.xml · nonDerivative · entry 1 WITEK THEODORE L JR · CIK 0001612452 · Sr. VP & Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,131 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.